Comparative Pharmacology
Head-to-head clinical analysis: RELAFEN versus RIMADYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RELAFEN versus RIMADYL.
RELAFEN vs RIMADYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nabumetone is a nonacidic nonsteroidal anti-inflammatory drug (NSAID) that is a prodrug, rapidly metabolized to the active metabolite 6-methoxy-2-naphthylacetic acid (6-MNA), which inhibits cyclooxygenase (COX) and thereby prostaglandin synthesis.
Selective cyclooxygenase-2 (COX-2) inhibitor, reducing prostaglandin synthesis involved in inflammation, pain, and fever.
1000 mg orally once daily, or 500 mg twice daily. Maximum dose 2000 mg/day.
50-100 mg orally twice daily, or 100-200 mg rectally once daily (suppository).
None Documented
None Documented
Terminal elimination half-life approximately 24 hours (range 20-30 hours), allowing once-daily dosing.
Terminal elimination half-life: 12–18 hours in dogs at recommended doses. Clinical context: Supports twice-daily dosing; longer half-life in some breeds may require dose adjustment.
Primarily renal (90% as metabolites, ~5% unchanged); biliary/fecal minor (<5%).
Primarily hepatic metabolism (oxidation, conjugation) with ~70% of metabolites excreted in urine and ~30% in feces via biliary elimination. Less than 5% excreted unchanged.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)